Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026)

Revolution Medicines has reported Other Accumulated Expenses for 8 years, with the latest figure at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 400.92% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 400.92% YoY), and the FY2025 full-year result was $7.9 million, up 1247.86% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.3 million, down from $7.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.2 million in Q3 2025, with the low at $280000.0 in Q1 2022.
• Average Other Accumulated Expenses over 5 years is $1.8 million, with a median of $647000.0 recorded in 2022.
• Year-over-year, Other Accumulated Expenses slumped 85.04% in 2024 and jumped 1247.86% in 2025.
• Tracing RVMD's Other Accumulated Expenses over 5 years: stood at $505000.0 in 2022, then soared by 671.49% to $3.9 million in 2023, then tumbled by 85.04% to $583000.0 in 2024, then jumped by 1247.86% to $7.9 million in 2025, then sank by 58.5% to $3.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.3 million (Q1 2026), $7.9 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.

Peer Comparison